As the race for marijuana infused beverages heats up, one company in the US shared a confident vision in its latest technology upgrade.
Last Thursday (July 25), Denver, Colorado-based Dixie Brands (CSE:DIXI.U,OTCQX:DXBRF) announced it found a new breakthrough in the solubility and time delivery of its upcoming cannabis FUSE drink lineup.
This new line of products will be water soluble drink additives containing THC, with several units and product types. This additive will behave the same as other currently sold non-cannabis flavor additives.
Chuck Smith, CEO of Dixie, told the Investing News Network (INN) that cannabis companies are all targeting a standardized delivery period with the edibles and infused products as a way to make consumers more comfortable with the items.
Experts of the beverage space agree that on-take and off-take time from the moment a consumer drinks a cannabis infused beverage will be critical in determining successful brands.
“In the beverage space, if you drink alcohol you know what happens when you have a couple of glasses of wine … and we want to be able to mimic that experience as close as possible,” Smith said.
Dixie already offers a variety of “elixir” THC beverages in California, Colorado, Nevada and Maryland with distinct flavours like root beer and fruit punch.
“In this case we’ll have flavoured THC as well as non-flavored THC drink additives. If somebody has tea or coffee or … orange juice and they want to put some THC in it, they’ll be able to do that,” Smith told INN.
Despite the large interest for these drinks from cannabis companies and even some established beverage makers, critics point to low sales figures from thriving US markets, indicating that infused drinks will not attract consumers as much as predicted.
Smith told INN he views these numbers as having been affected by the fractured state of the US cannabis market due to the federal illegality of the drug.
“The format for beverages hasn’t become as consumer friendly in the THC world as it is in the alcohol space,” said Smith. “We think that’s going to change. We think ultimately consumers are going to be able to go into a consumption lounge and order a THC beverage.”
Smith has high aspirations for his company’s drink additive and its ability to aid the social consumption challenges for all cannabis drinks. Dixie’s line of FUSE products is set to launch in Q4 this year.
When asked about the overall significance for cannabis infused drinks, Smith admitted while it’s an important product category it’s not the biggest one.
“The sociability and the social use of cannabis infused beverages will increase, but right now they are very restrictive,” he said.
The FUSE line of products doesn’t represent the first foray for the company or its brand portfolio exploring the beverage market. In May, the company announced its subsidiary Aceso Hemp launched Fizz Tabs, a dissolvable hemp-derived CBD infused tablet for the health and wellness space.
While Dixie has a focus on the US, its portfolio of brands will still gain a presence in the Canadian cannabis market thanks to a partnership with Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF).
In May 2018, Auxly gained the exclusive license to Dixie’s lineup of cannabis-infused products.
Last Thursday as well, Auxly announced a critical C$123 million investment transaction from England-based tobacco company Imperial Brands (LSE:IMB,OTCQX:IMBBF). This deal will grant Auxly access to the vaporizer technology from Imperial.
Smith confirmed to INN that, while it’s too early to determine which exact products will be available on day one, the company wants all products and brands it owns to be sold in every market possible.
The Canadian federal government will legalize edibles and infused cannabis products to consumers on October 17. However, Health Canada, the federal agency tasked with overseeing the regulations of the industry, projects sales won’t actually begin until sometime around mid-December.
Shortly after the draft regulations on Canadian edibles became available, Dixie confirmed to investors last December it anticipates to launch a full plethora of THC and CBD items as part of its relationship with Auxly.
In June, a projection from industry research company Deloitte pegged the cannabis edibles and infused market at a value of C$2.7 billion in Canada per year. From that, edibles alone will represent C$1.6 billion a year. Cannabis infused beverages will be worth C$529 million per year, according to the research.
Dixie started trading in Canada last year, at the height of US-based companies listing on the Canadian Securities Exchange. So far this year, shares of the company have increased in value 21.57 percent on the back of continuous expansion in the US market.
As part of its most recent quarterly financial update to investors, the company reported a net loss of US$6.7 million for its Q1 2019. However, revenues for the firm rose 40 percent from the previous quarter to US$2.3 million. At the end of March the company held just over US$5 million in cash.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.